Semaglutide Significantly Reduces Cardiovascular Events in Obese Adults Without Diabetes

Obesity is a major global health challenge, significantly increasing the risk of cardiovascular disease (CVD), including heart attack and stroke. While semaglutide (a GLP-1 receptor agonist) is known for its efficacy in weight loss and type 2 diabetes management, its direct impact on cardiovascular outcomes in individuals with obesity but without diabetes has been less clear. This study aimed to evaluate the cardiovascular benefits of semaglutide in a population with overweight or obesity and established cardiovascular disease but without diabetes.

The study found a significant reduction in major adverse cardiovascular events (MACE) in the semaglutide group. The primary composite endpoint occurred in 6.5% of participants receiving semaglutide compared to 8.0% in the placebo group. This represents a 20% relative risk reduction (Hazard Ratio 0.80, 95% CI 0.72-0.90, p<0.001). The most important finding was that semaglutide significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% in individuals with obesity and pre-existing CVD but without diabetes. Specifically, cardiovascular death was reduced by 15% (HR 0.85, 95% CI 0.71-1.01), non-fatal myocardial infarction by 28% (HR 0.72, 95% CI 0.61-0.85), and non-fatal stroke by 7% (HR 0.93, 95% CI 0.74-1.16). Participants on semaglutide also achieved an average weight loss of 9.4% from baseline, compared to 0.8% in the placebo group, demonstrating its dual benefit.